Daniel P Nguyen1, Emily A Vertosick2, Renato B Corradi3, Antoni Vilaseca3, Nicole E Benfante3, Karim A Touijer4, Daniel D Sjoberg2, Paul Russo4. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, University of Bern, Bern, Switzerland. Electronic address: daniel.nguyen@insel.ch. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
Abstract
OBJECTIVES: To analyze whether the histological subtype of renal cell carcinoma (RCC) affects survival after surgical resection in contemporary patients, and if so, whether prognostic significance differs according to the type of surgical resection or tumor stage. MATERIALS AND METHODS: From 2006 to 2014, 2,237 patients underwent surgical resection (25% radical nephrectomy and 75% partial nephrectomy [PN]) for nonmetastatic RCC at a tertiary referral center. Estimated survival function curves and Cox regression models evaluated the effect of histological subtype on recurrence-free survival (RFS) and overall survival (OS). Interaction analyses tested whether the effect of histological subtype depends on the type of surgical resection or tumor stage. RESULTS: Patients with RCC stage T2 or lower and those with low-grade conventional clear cell, papillary or chromophobe RCC of any stage had 5-year RFS probabilities>90%. Patients with clear cell papillary RCC stage T3 or greater had predicted 5-year RFS of 81%. However, 5-year OS probabilities were>94% for clear cell papillary RCC of any stage. High-grade conventional clear cell and papillary RCC stage T2 or lower, low-grade conventional clear cell and chromophobe RCC of any stage conferred 5-year OS probabilities of >93%. Unclassified RCC demonstrated the lowest OS probabilities at any stage. In multivariable analyses, histological subtype affected RFS (P<0.0001) and OS (P = 0.026) following surgical resection, with no differences in this association for radical nephrectomy vs. PN (RFS, P = 0.2; OS, P = 0.4), and across pathologic stages (RFS, P = 0.1; OS, P = 0.3). Compared with low-grade conventional clear cell RCC, chromophobe (hazard ratio [HR] = 0.72, 95% CI: 0.30-1.75) and papillary RCC (HR = 0.30, 95% CI: 0.09-0.97) conferred lower risk of recurrence. Chromophobe (HR = 0.67, 95% CI: 0.30-1.52) and clear cell papillary RCC (HR = 0.91, 95% CI: 0.12-6.78) conferred the lowest risk of all-cause mortality. CONCLUSIONS: In the era of PN for RCC, histological subtype remained a significant predictor of survival, regardless of type of surgical resection or tumor stage.
OBJECTIVES: To analyze whether the histological subtype of renal cell carcinoma (RCC) affects survival after surgical resection in contemporary patients, and if so, whether prognostic significance differs according to the type of surgical resection or tumor stage. MATERIALS AND METHODS: From 2006 to 2014, 2,237 patients underwent surgical resection (25% radical nephrectomy and 75% partial nephrectomy [PN]) for nonmetastatic RCC at a tertiary referral center. Estimated survival function curves and Cox regression models evaluated the effect of histological subtype on recurrence-free survival (RFS) and overall survival (OS). Interaction analyses tested whether the effect of histological subtype depends on the type of surgical resection or tumor stage. RESULTS:Patients with RCC stage T2 or lower and those with low-grade conventional clear cell, papillary or chromophobe RCC of any stage had 5-year RFS probabilities>90%. Patients with clear cell papillary RCC stage T3 or greater had predicted 5-year RFS of 81%. However, 5-year OS probabilities were>94% for clear cell papillary RCC of any stage. High-grade conventional clear cell and papillary RCC stage T2 or lower, low-grade conventional clear cell and chromophobe RCC of any stage conferred 5-year OS probabilities of >93%. Unclassified RCC demonstrated the lowest OS probabilities at any stage. In multivariable analyses, histological subtype affected RFS (P<0.0001) and OS (P = 0.026) following surgical resection, with no differences in this association for radical nephrectomy vs. PN (RFS, P = 0.2; OS, P = 0.4), and across pathologic stages (RFS, P = 0.1; OS, P = 0.3). Compared with low-grade conventional clear cell RCC, chromophobe (hazard ratio [HR] = 0.72, 95% CI: 0.30-1.75) and papillary RCC (HR = 0.30, 95% CI: 0.09-0.97) conferred lower risk of recurrence. Chromophobe (HR = 0.67, 95% CI: 0.30-1.52) and clear cell papillary RCC (HR = 0.91, 95% CI: 0.12-6.78) conferred the lowest risk of all-cause mortality. CONCLUSIONS: In the era of PN for RCC, histological subtype remained a significant predictor of survival, regardless of type of surgical resection or tumor stage.
Authors: John R Srigley; Brett Delahunt; John N Eble; Lars Egevad; Jonathan I Epstein; David Grignon; Ondrej Hes; Holger Moch; Rodolfo Montironi; Satish K Tickoo; Ming Zhou; Pedram Argani Journal: Am J Surg Pathol Date: 2013-10 Impact factor: 6.394
Authors: Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville Journal: J Urol Date: 2010-02-19 Impact factor: 7.450
Authors: Satish K Tickoo; Mariza N dePeralta-Venturina; Lara R Harik; Heath D Worcester; Mohamed E Salama; Andrew N Young; Holger Moch; Mahul B Amin Journal: Am J Surg Pathol Date: 2006-02 Impact factor: 6.394
Authors: Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch Journal: Am J Surg Pathol Date: 2015-07 Impact factor: 6.394
Authors: Maxine Sun; Shahrokh F Shariat; Christopher Cheng; Vincenzo Ficarra; Masaru Murai; Stéphane Oudard; Allan J Pantuck; Richard Zigeuner; Pierre I Karakiewicz Journal: Eur Urol Date: 2011-06-30 Impact factor: 20.096
Authors: William R Sukov; Christine M Lohse; Bradley C Leibovich; R Houston Thompson; John C Cheville Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar Journal: J Pathol Date: 1997-10 Impact factor: 7.996
Authors: Maxime Crépel; Hendrik Isbarn; Umberto Capitanio; Daniel Liberman; Claudio Jeldres; Maxine Sun; Shahrokh F Shariat; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-07-22 Impact factor: 2.649
Authors: Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Karim Touijer; Didier Jacqmin; Louis R Kavoussi; Francesco Montorsi; Jean Jacques Patard; Craig G Rogers; Paul Russo; Robert G Uzzo; Hendrik Van Poppel Journal: Eur Urol Date: 2009-10-20 Impact factor: 20.096
Authors: Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau Journal: Can Urol Assoc J Date: 2018-05-31 Impact factor: 1.862
Authors: Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2017-04-27 Impact factor: 4.553
Authors: Paolo Capogrosso; Alessandro Larcher; Daniel D Sjoberg; Emily A Vertosick; Francesco Cianflone; Paolo Dell'Oglio; Cristina Carenzi; Andrea Salonia; Andrew J Vickers; Francesco Montorsi; Roberto Bertini; Umberto Capitanio Journal: J Urol Date: 2018-01-31 Impact factor: 7.450
Authors: Michael Siev; Audrey Renson; Hung-Jui Tan; Tracy L Rose; Stella K Kang; William C Huang; Marc A Bjurlin Journal: Kidney Cancer Date: 2020-03-30
Authors: Ricardo G Alvim; Amy L Tin; Lucas Nogueira; Nathan C Wong; Renato C Fonseca; Daniel D Sjoberg; A Ari Hakimi; Karim A Touijer; Paul Russo; Jonathan A Coleman Journal: Urology Date: 2021-07-29 Impact factor: 2.649
Authors: Ashley Di Meo; Rola Saleeb; Samantha J Wala; Heba W Khella; Qiang Ding; Haiyan Zhai; Kalra Krishan; Adriana Krizova; Manal Gabril; Andrew Evans; Fadi Brimo; Maria D Pasic; Antonio Finelli; Eleftherios P Diamandis; George M Yousef Journal: Oncotarget Date: 2017-12-08